Literature DB >> 12209602

Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis.

Benedetta Bussolati1, Simona Russo, Ilaria Deambrosis, Vincenzo Cantaluppi, Alessandro Volpe, Ugo Ferrando, Giovanni Camussi.   

Abstract

CD40 activation by CD154 may trigger diverse cellular responses, ranging from proliferation and differentiation to growth suppression and cell death, in normal and malignant cells. However, the pathophysiologic role of CD154 expressed by tumor cells remains unclear. We have investigated the expression of the CD40-CD154 system in 24 primary cultures derived from renal cell carcinomas, its correlation with tumor stage and its potential functional significance. We found coexpression of CD40 and CD154 in most of the renal carcinoma cell lines. CD154, but not CD40 expression, significantly correlated with tumor stage. Moreover, renal carcinoma cell lines also released the soluble form of CD154 into the supernatant. CD40 engagement by CD154 did not affect apoptosis or survival. On the contrary, CD154 stimulated cell proliferation, motility and production of PAF, a phospholipid mediator of inflammation with angiogenic properties. Furthermore, the renal carcinoma cell lines expressed PAF-R. Blockade of PAF-R by WEB-2170, a PAF-R antagonist, abolished the CD154-dependent motility, indicating a role for PAF synthesized after CD154 stimulation in renal carcinoma cell motility. In conclusion, this study identifies new functional properties for CD154, which are potentially relevant for the growth and dissemination of renal carcinoma cells. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209602     DOI: 10.1002/ijc.10545

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis.

Authors:  Valentina Fonsato; Stefano Buttiglieri; Maria Chiara Deregibus; Valeria Puntorieri; Benedetta Bussolati; Giovanni Camussi
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 2.  Mechanisms and biomarkers of cancer-associated thrombosis.

Authors:  Ann S Kim; Alok A Khorana; Keith R McCrae
Journal:  Transl Res       Date:  2020-07-06       Impact factor: 7.012

3.  CD133+ renal progenitor cells contribute to tumor angiogenesis.

Authors:  Stefania Bruno; Benedetta Bussolati; Cristina Grange; Federica Collino; Manuela Efrem Graziano; Ugo Ferrando; Giovanni Camussi
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 4.  The role of platelet-activating factor in mesangial pathophysiology.

Authors:  Anna Reznichenko; Ron Korstanje
Journal:  Am J Pathol       Date:  2015-02-02       Impact factor: 4.307

Review 5.  The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis
Journal:  Adv Nutr       Date:  2019-01-01       Impact factor: 8.701

6.  CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.

Authors:  Jonathan M Weiss; W Gregory Alvord; Octavio A Quiñones; Jimmy K Stauffer; Robert H Wiltrout
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

7.  Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154.

Authors:  Ilaria Deambrosis; Sara Lamorte; Fulvia Giaretta; Lorenzo Tei; Luigi Biancone; Benedetta Bussolati; Giovanni Camussi
Journal:  J Mol Med (Berl)       Date:  2008-11-05       Impact factor: 4.599

8.  Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.

Authors:  Ilia N Buhtoiarov; Alexander L Rakhmilevich; Lewis L Lanier; Erik A Ranheim; Paul M Sondel
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

9.  Extracellular vesicles derived from renal cancer stem cells induce a pro-tumorigenic phenotype in mesenchymal stromal cells.

Authors:  Rafael Soares Lindoso; Federica Collino; Giovanni Camussi
Journal:  Oncotarget       Date:  2015-04-10

10.  Palliation of bone cancer pain by antagonists of platelet-activating factor receptors.

Authors:  Katsuya Morita; Seiji Shiraishi; Naoyo Motoyama; Tomoya Kitayama; Takashi Kanematsu; Yasuhito Uezono; Toshihiro Dohi
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.